STERIS plc 10-K — AI Bull & Bear Analysis

The fiscal 2026 10-K presents a company in the midst of a high-stakes transition. While STERIS has improved its margin profile and streamlined operations through key divestitures, the financial risk remains concentrated in its leveraged balance sheet and the binary nature of its regulatory environment. The company's ability to generate $982.9 million in free cash flow provides a necessary cushion, but the scale of its debt obligations requires flawless execution of its operational turnaround. Ultimately, the investment case hinges on whether the growth in recurring revenue and the success of the Improvement framework can outpace the cost of debt and potential regulatory disruptions. The shift toward a more predictable revenue stream is a positive structural change, but the looming 2028-2031 debt maturities and the EPA's review of ethylene oxide create a volatile backdrop for investors.